[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX2007012537A - Combinaciones, metodos y composiciones para tratamiento del cancer. - Google Patents

Combinaciones, metodos y composiciones para tratamiento del cancer.

Info

Publication number
MX2007012537A
MX2007012537A MX2007012537A MX2007012537A MX2007012537A MX 2007012537 A MX2007012537 A MX 2007012537A MX 2007012537 A MX2007012537 A MX 2007012537A MX 2007012537 A MX2007012537 A MX 2007012537A MX 2007012537 A MX2007012537 A MX 2007012537A
Authority
MX
Mexico
Prior art keywords
methods
compositions
combinations
treating cancer
bcr
Prior art date
Application number
MX2007012537A
Other languages
English (en)
Inventor
Francis Y Lee
Roberto Weinmann
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of MX2007012537A publication Critical patent/MX2007012537A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La invencion se refiere a una combinacion del inhibidor BCR-ABL, ejemplificado por 'N-(2-Cloro-6-metilfenil)-2-[[6-[4-(2-hidroxieti l)-1-piperazinil)-2-metil-4-pirimidinil)amino-5-tiazolcarboxamida y/u otros inhibidores BCR/ABL, y un citotoxico selectivo de celula madre, ejemplificado por sal de clorohidrato de (R)-2,3,4,5-tetrahidro-1-(1H-imidazol-4-ilmetil)-3-(fenilmetil)-4 -(2-tienilsulfonil)-1H-,4-benzodiazepin-7-carbonitrilo, y otros agentes citotoxicos de celula madre, composiciones farmaceuticas de la combinacion y a metodos para usar las composiciones farmaceuticas en el tratamiento de trastornos oncologicos.
MX2007012537A 2005-04-13 2006-04-13 Combinaciones, metodos y composiciones para tratamiento del cancer. MX2007012537A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US67074405P 2005-04-13 2005-04-13
US74843305P 2005-12-08 2005-12-08
US11/402,502 US20060235006A1 (en) 2005-04-13 2006-04-12 Combinations, methods and compositions for treating cancer
PCT/US2006/013773 WO2006113304A2 (en) 2005-04-13 2006-04-13 Combinations, methods and compositions for treating cancer

Publications (1)

Publication Number Publication Date
MX2007012537A true MX2007012537A (es) 2007-12-10

Family

ID=37109315

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007012537A MX2007012537A (es) 2005-04-13 2006-04-13 Combinaciones, metodos y composiciones para tratamiento del cancer.

Country Status (12)

Country Link
US (2) US20060235006A1 (es)
EP (1) EP1868435A4 (es)
JP (1) JP2008536853A (es)
KR (1) KR20080004495A (es)
AU (1) AU2006236812A1 (es)
BR (1) BRPI0608176A2 (es)
CA (1) CA2604581A1 (es)
EA (1) EA200702238A1 (es)
MX (1) MX2007012537A (es)
NO (1) NO20075087L (es)
TW (1) TW200722091A (es)
WO (1) WO2006113304A2 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1348370A (zh) 1999-04-15 2002-05-08 布里斯托尔-迈尔斯斯奎布公司 环状蛋白酪氨酸激酶抑制剂
DE602006021142D1 (de) 2005-02-03 2011-05-19 Gen Hospital Corp Verfahren zur behandlung von gefitinib-resistentem krebs
US8247419B2 (en) * 2005-06-09 2012-08-21 Bristol-Myers Squibb Company Methods of identifying and treating individuals exhibiting mutant kit protein
RU2451524C2 (ru) 2005-11-04 2012-05-27 Вайет Противоопухолевые комбинации с ингибиторами mtor, герцептином и/или hki-272
US20090099197A1 (en) * 2005-11-15 2009-04-16 Bristol-Myers Squibb Company Methods of Identifying and Treating Individuals Exhibiting MDR-1 Overexpression With Protein Tyrosine Kinase Inhibitors and Combinations Thereof
CN102861338A (zh) * 2006-04-05 2013-01-09 诺瓦提斯公司 用于治疗癌症、包含bcr-abl/c-kit/pdgf-r tk抑制剂的组合
WO2007116025A2 (en) * 2006-04-07 2007-10-18 Novartis Ag Use of c-src inhibitors in combination with a pyrimidylaminobenzamide compound for the treatment of leukemia
WO2008064004A2 (en) * 2006-11-16 2008-05-29 Wyeth 4-anilino-3-quinolinecarbonitriles for the treatment of acute myelogenous leukemia (aml)
US20080119463A1 (en) * 2006-11-16 2008-05-22 Wyeth 4-Anilino-3-quinolinecarbonitriles for the treatment of acute myelogenous leukemia (AML)
WO2008089135A2 (en) * 2007-01-12 2008-07-24 University Of South Florida Identification of biomarkers predictive of dasatinib effects in cancer cells
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
WO2009076373A1 (en) * 2007-12-10 2009-06-18 Concert Pharmaceuticals Inc. Heterocyclic kinase inhibitors
KR101922096B1 (ko) 2008-06-17 2018-11-27 와이어쓰 엘엘씨 Ｈｋｉ-272 및 비노렐빈을 함유하는 항신생물성 조합물
US8119129B2 (en) * 2008-08-01 2012-02-21 Bristol-Myers Squibb Company Combination of anti-CTLA4 antibody with dasatinib for the treatment of proliferative diseases
PL2326329T3 (pl) * 2008-08-04 2017-07-31 Wyeth Llc Przeciwnowotworowe połączenia 4-anilino-3-cyjanochinolin i kapecytabiny
WO2010077894A2 (en) * 2008-12-16 2010-07-08 Bristol-Myers Squibb Company Methods of inhibiting quiescent tumor proliferation
EP3659596A1 (en) * 2009-07-20 2020-06-03 Bristol-Myers Squibb Company Combination of anti-ctla4 antibody with paclitaxel for the synergistic treatment of proliferative diseases
AU2010302961A1 (en) * 2009-10-01 2012-04-19 Csl Limited Method of treatment of philadelphia chromosome positive leukaemia

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6011029A (en) * 1996-02-26 2000-01-04 Bristol-Myers Squibb Company Inhibitors of farnesyl protein transferase
US7125875B2 (en) * 1999-04-15 2006-10-24 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
CN1348370A (zh) * 1999-04-15 2002-05-08 布里斯托尔-迈尔斯斯奎布公司 环状蛋白酪氨酸激酶抑制剂
TWI310684B (en) * 2000-03-27 2009-06-11 Bristol Myers Squibb Co Synergistic pharmaceutical kits for treating cancer
NZ529145A (en) * 2001-05-16 2005-07-29 Novartis Ag Combination comprising N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)- 2pyrimidine-amine and a chemotherapeutic agent
WO2004015130A2 (en) * 2002-08-07 2004-02-19 Exelixis Modulators of rabggt and methods of use thereof
US20050009891A1 (en) * 2003-07-09 2005-01-13 Lee Francis Y. Combination of SRC Kinase inhibitors and chemotherapeutic agents for the treatment of proliferative diseases
MY144177A (en) * 2004-02-04 2011-08-15 Novartis Ag Salt forms of 4-(4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide.
US7491725B2 (en) * 2004-02-06 2009-02-17 Bristol-Myers Squibb Company Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors
TW200628156A (en) * 2004-11-04 2006-08-16 Bristol Myers Squibb Co Combination of a SRC kinase inhibitor and a BCR-ABL inhibitor for the treatment of proliferative diseases

Also Published As

Publication number Publication date
TW200722091A (en) 2007-06-16
US20060235006A1 (en) 2006-10-19
NO20075087L (no) 2008-01-09
WO2006113304A3 (en) 2007-08-02
US20090054415A1 (en) 2009-02-26
WO2006113304A2 (en) 2006-10-26
EP1868435A4 (en) 2009-04-01
AU2006236812A1 (en) 2006-10-26
CA2604581A1 (en) 2006-10-26
KR20080004495A (ko) 2008-01-09
JP2008536853A (ja) 2008-09-11
EA200702238A1 (ru) 2008-04-28
BRPI0608176A2 (pt) 2009-11-17
EP1868435A2 (en) 2007-12-26

Similar Documents

Publication Publication Date Title
MX2007012537A (es) Combinaciones, metodos y composiciones para tratamiento del cancer.
GEP20104927B (en) Formulations of a src/abl inhibitor
IL194744A (en) Derivatives 1– (alkyl) –3– (amino-converted) –5– (converted) - s-triazole, a process for their preparation and pharmacological preparations containing them for the treatment of psychotic diseases
PE20061394A1 (es) Metabolitos de n-(2-cloro-6-metilfenil)-2-[[6-[4-(2-hidroxietil)-1-piperazinil]-2-metil-4-pirimidinil]amino]-5-tiazolcarboxamidas
AP1545A (en) Hydrochloride salts of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione.
EA200800727A1 (ru) Введение ингибиторов дипептидилпептидазы
IL205697A0 (en) 4(-3-(-2-(phenyl)morpholino)-2-oxopyrrolidin-1-yl)-n-(thiazole-2-yl)benzenesulfon-amide derivatives, compositions comprising the same and uses thereof
AR104566A2 (es) Forma cristalina de la sal diclorhidrato de ((1s)-1-(((2s)-2-(5-(4-(2-((2s)-1-((2s)-2-((metoxicarbonil)amino)-3-metilbutanoil)-2-pirrolidinil)-1h-imidazol-5-il)-4-bifenilil)-1h-imidazol-2-il)-1-pirrolidinil)carbonil)-2-metilpropil)carbamato de metilo
SG162790A1 (en) Aspartyl protease inhibitors
ATE481093T1 (de) Vervendung von dexrazoxane in der prävention und behandlung der alzeheimer-krankheit
EA200702568A1 (ru) Гетеробициклические ингибиторы металлопротеазы и их применение
NO20084853L (no) Forbindelser som er agonister av muscarinreseptorer og som kan vaere effektive i behandling av smerte, Alzheimers sykdom og/eller schizofreni
TN2009000225A1 (en) Compounds and compositions as protein kinase kinase inhibitors
EA201100688A1 (ru) Соединения и композиции в качестве ингибиторов протеинкиназы
WO2007125310A3 (en) Pharmaceutical combinations of pk inhibitors and other active agents
NO20092412L (no) Hydantoinderivater anvendes som MMP-inhibitorer
PE20120635A1 (es) Dihidropirazolonas sustituidas como inhibidores de hif-propil-4-hidroxilasas
NO20084923L (no) N-(2-thiazolyl)-amid derivater som GSK-3 inhibitorer
EP1951709A4 (en) IMIDAZOLIDINONE COMPOUNDS USEFUL AS BETA-SECRETASE INHIBITORS IN THE TREATMENT OF ALZHEIMER'S DISEASE
PE20110433A1 (es) Antagonistas de la via hedgehog de ftalazina disustituida
WO2007068728A3 (en) N-substituted pyrrolopyridinones active as kinase inhibitors
MX2009012525A (es) Pirazol-pirrolidinas como inhibidores de gamma secretasa.
PE20091617A1 (es) Tiazolil-dihidro-indazoles
TW200730507A (en) Pyrimidine derivatives for the treatment of abnormal cell growth
BRPI0614481A2 (pt) composto, composição farmecêutica, uso do composto, e, método de tratamento de distúrbios mediados por mglur5

Legal Events

Date Code Title Description
FA Abandonment or withdrawal